Investors will have a direct line to management teams from seven life sciences companies on Thursday, September 17, 2026, when the Life Sciences Virtual Investor Forum takes place online. Hosted by Virtual Investor Conferences, the event is a B2i Digital Featured Conference, with B2i Digital serving as the Official Marketing Partner. The forum runs live 30-minute sessions with audience Q&A, and replays will be available on the B2i Digital and OTC Markets YouTube channels.
The lineup highlights a range of therapeutic approaches and technologies. Sona Nanotech Inc. will present a photothermal cancer therapy built on gold nanorods. Raphael Pharmaceutical will discuss cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease. Amplia Therapeutics Ltd. will share its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis. Adaptin Bio, Inc. will present precision drug delivery technologies aimed at target tissues including behind the blood-brain barrier.
Other presenters include Acurx Pharmaceuticals, Inc., which is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens, and CytoDyn Inc., which is studying a humanized monoclonal antibody in solid-tumor oncology. 4DMedical Ltd. will showcase FDA-cleared four-dimensional respiratory imaging.
The forum matters because it offers investors a live, unfiltered look at companies that are often difficult to evaluate through filings alone. "Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company," said David Shapiro, Chief Executive Officer of B2i Digital, Inc. "My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind."
For investors, the event provides a rare opportunity to ask questions directly to executives and to compare multiple companies in a single afternoon. The presenting companies span early-stage and clinical-stage development across oncology, fibrosis, antibiotics, drug delivery, cannabinoid therapeutics, and respiratory imaging. Each 30-minute session includes a presentation followed by live Q&A, and replays allow investors to review details on demand.
The forum also underscores the global nature of life sciences investing. Virtual Investor Conferences throughout the year feature public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and the OTC Markets. Virtual Investor Conferences is an OTC Markets Group Inc. property.
Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. Registration is open at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. The schedule, subject to change, begins at 11:00 AM ET with Sona Nanotech Inc., followed by Raphael Pharmaceutical at 11:30 AM ET, Amplia Therapeutics Ltd. at 2:00 PM ET, Adaptin Bio, Inc. at 2:30 PM ET, Acurx Pharmaceuticals, Inc. at 3:00 PM ET, CytoDyn Inc. at 3:30 PM ET, and 4DMedical Ltd. at 4:00 PM ET.
B2i Digital, Inc. is not an affiliate of Virtual Investor Conferences and is not authorized to represent or act on behalf of Virtual Investor Conferences in any capacity. Content related to any specific company referenced was provided by that company, approved by that company, or obtained from publicly available sources. B2i Digital, Inc. has not independently verified the accuracy or completeness of such information. This content is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. B2i Digital, Inc. is not a registered broker-dealer, investment adviser, or financial adviser, and nothing herein should be construed as investment, legal, tax, or accounting advice. Readers should consult their own advisers and conduct their own due diligence before making any investment decision.
